Roundtable Discussion: Kuzel Walks Through New Treatment Options in Advanced RCC
March 30th 2022During a Targeted Oncology case-based roundtable event, Timothy Kuzel, MD, discussed risk assessment and later-line treatment options for a patient diagnosed with metastatic renal cell carcinoma who received lenvatinib and pembrolizumab.
Siefker-Radtke Discusses the Role of Antibody-Drug Conjugates in Urothelial Carcinoma
March 25th 2022During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.
Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL
March 22nd 2022During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.
Roundtable Discussion: Salit Explores Use of Steroids and Therapy for Acute GVHD
March 19th 2022During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.
Hanna Discusses Efficacy Results of Different Treatments in RET-Positive Lung Cancer
February 19th 2022During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.